NCT04052048Recruiting
Active Surveillance SNEP Assay Registry Trial for Prostate Cancer
A Multi-center, Prospective Active Surveillance Registry Trial Assessing the Performance of a Non-invasive Immunogenomic Blood Test for Indolent Prostate Cancer Disease Management.
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
A multi-center, prospective active surveillance registry trial assessing the performance of a non-invasive blood test for indolent prostate cancer disease management.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 7 Aug 2019
- Start date
- 9 Sept 2019
- Primary completion date
- 15 Nov 2026
- Lead sponsor
- Immunis.AI
- Diseases
- Prostate cancer
- NCT number
- NCT04052048
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 9 Sept 2019 to the primary completion date, 15 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Men on watchful waiting i.e. those with less than 10-year life expectancy with no intent for curative therapy
Other illness
- Men with symptoms or rising PSA who have not been proven to have cancer by tissue biopsy i.e. men with only negative prostate biopsies.
- Patients with a history of a different cancer (except basal cell carcinoma)
Who the study is looking for
- Men between 40-80 of age with at least a 10-year life expectancy
- All active surveillance protocols are accepted
- No PSA limits
- Category 1:
- Patient is currently on active surveillance with only ONE previous low grade prostate biopsy.
- Patient must already be scheduled for their 1st annual biopsy under their active surveillance protocol within 90 days of enrollment date.
- Category 2:
- Patient is recently diagnosed with low grade prostate cancer but has decided against active surveillance and is scheduled for radical prostatectomy within 90 days of enrollment date.
Age in the registry: 40 years to 80 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Comprehensive Urology Coordinator of this site? Confirm its status | Royal Oak | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.